Clinical trial
Open-label Extension to Protocol 1042-0500
NCT00442104 · Marinus Pharmaceuticals, Industry · Terminated
Key facts
| NCT number | NCT00442104 |
|---|---|
| Title | Open-label Extension to Protocol 1042-0500 |
| Official title | An Open-label Clinical Study to Evaluate the Safety and Antiepileptic Activity of Ganaxolone in Treatment of Patients Diagnosed With Infantile Spasms. |
| Lead sponsor | Marinus Pharmaceuticals, Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Infantile Spasms |
| Intervention type | Drug |
| Interventions | Ganaxolone |
| Enrollment | 54 |
| Start date | Jan 1, 2007 |
| Primary completion | Mar 1, 2009 |
| Completion | Mar 1, 2009 |
| First posted | Mar 1, 2007 |
| Last update posted | May 28, 2024 |
| Countries | United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: